Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02143778 · ClinicalTrials.gov registry record · NA
Assessing Portal Hypertension With Methacetin Breath Test
A NA study, sponsored by Meridian Bioscience.
- Completed
- Registry status
- NA
- Development phase
- 246
- Enrollment target
NCT02143778 is a NA study that has completed, run by Meridian Bioscience. The registered enrollment target is 246 participants.
The verdict
NCT02143778, a NA study, has completed, sponsored by Meridian Bioscience.
- COMPLETED
- Registry status
- NA
- Development phase
- 246 participants
- Enrollment target
Study Summary
This study will be used to train an algorithm using Methacetin breath test (MBT) measures and to select a cut-off to determine presence or absence of Clinically Significant Portal Hypertension (CSPH) as defined by Hepatic Venous Gradient Pressure (HVPG) ≥ 10mmHg,
Interventions
- DEVICE Methacetin Breath Test
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 246 participants |
| Start Date | 2014-11 |
| Est. Completion | 2019-01 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02143778
The ClinicalTrials.gov registry entry for NCT02143778 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 246 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Meridian Bioscience, which has 19 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Methacetin Breath Test is the first listed.
NCT02143778 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02143778 about?
NCT02143778 is a clinical study titled "Assessing Portal Hypertension With Methacetin Breath Test". This study will be used to train an algorithm using Methacetin breath test (MBT) measures and to select a cut-off to determine presence or absence of Clinically Significant Portal Hypertension (CSPH) as defined by Hepatic Venous Gradient Pressure (HVPG) ≥ 10mmHg,
What is the current status of trial NCT02143778?
This trial is currently completed. It is a NA study. The enrollment target is 246 participants. The study started on 2014-11. Estimated completion is 2019-01.
What interventions are being tested in trial NCT02143778?
The interventions under investigation include: Methacetin Breath Test (DEVICE).
Who is sponsoring clinical trial NCT02143778?
This trial is sponsored by Meridian Bioscience, which has 19 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.